Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)

May 11, 2026
Read More
April 22, 2026

Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting

Read More
March 26, 2026

Sironax Appoints Clive Wang to Board of Directors

Read More
March 20, 2026

Sironax Announces Upcoming Poster Presentation on NAMPT Activation

Read More
Learn More

Publications

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy adults and elderly participants

Clin Transl Sci., 2025

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Clin Transl Sci., 2024

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases

International Neurology & Brain Disorders Conference, 2024

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Journal of Intensive Medicine, 2024